Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enzon Pharmaceuticals ( (ENZND) ) has issued an update.
On April 10, 2026, Viskase Holdings, Inc. appointed long‑time executive Michael Blecic as Chief Financial Officer while he continues as Vice President, Chief Accounting Officer and Treasurer, consolidating financial oversight under a single, experienced leader without granting additional compensation beyond standard merit increases. On the same date, the company elevated Joseph D. King to Executive Vice President alongside his existing roles as Senior Vice President, General Counsel and Secretary, a move that formalized his expanded responsibilities and coincided with the termination of Mackenzie Stender’s interim CFO service through Silverman Consulting, Inc., signaling a shift from temporary to permanent leadership in key finance and legal positions.
More about Enzon Pharmaceuticals
Viskase Holdings, Inc. operates in the manufacturing sector through its wholly owned subsidiary Viskase Companies, LLC, with a focus on producing and supplying specialized products for its customer base. The company’s leadership structure includes roles overseeing accounting, treasury, legal and corporate governance functions, reflecting an emphasis on operational stability and regulatory compliance.
Average Trading Volume: 1,227
Technical Sentiment Signal: Sell
Current Market Cap: $112.5M
For an in-depth examination of ENZND stock, go to TipRanks’ Overview page.